BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33626541)

  • 21. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.
    Micke P; Mattsson JS; Edlund K; Lohr M; Jirström K; Berglund A; Botling J; Rahnenfuehrer J; Marincevic M; Pontén F; Ekman S; Hengstler J; Wöll S; Sahin U; Türeci O
    Int J Cancer; 2014 Nov; 135(9):2206-14. PubMed ID: 24710653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Contribution of
    Chen GL; Shen TC; Chang WS; Tsai CW; Li HT; Chuang CL; Lai YL; Yueh TC; Hsia TC; Wang SC; Bau DT
    Anticancer Res; 2018 Oct; 38(10):5671-5677. PubMed ID: 30275186
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exome-Wide Association Study Identifies Low-Frequency Coding Variants in 2p23.2 and 7p11.2 Associated with Survival of Non-Small Cell Lung Cancer Patients.
    Zhu M; Geng L; Shen W; Wang Y; Liu J; Cheng Y; Wang C; Dai J; Jin G; Hu Z; Ma H; Shen H
    J Thorac Oncol; 2017 Apr; 12(4):644-656. PubMed ID: 28104536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.
    Chan AW; Chau SL; Tong JH; Chow C; Kwan JSH; Chung LY; Lung RW; Tong CY; Tin EK; Law PP; Law WT; Ng CSH; Wan IYP; Mok TSK; To KF
    J Thorac Oncol; 2019 Jul; 14(7):1213-1222. PubMed ID: 30978501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of scavenger receptor MARCO defines a targetable tumor-associated macrophage subset in non-small cell lung cancer.
    La Fleur L; Boura VF; Alexeyenko A; Berglund A; Pontén V; Mattsson JSM; Djureinovic D; Persson J; Brunnström H; Isaksson J; Brandén E; Koyi H; Micke P; Karlsson MCI; Botling J
    Int J Cancer; 2018 Oct; 143(7):1741-1752. PubMed ID: 29667169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of survivin polymorphisms on non-small cell lung cancer survival.
    Dai J; Jin G; Dong J; Chen Y; Xu L; Hu Z; Shen H
    J Thorac Oncol; 2010 Nov; 5(11):1748-54. PubMed ID: 20881643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of high mobility group box - B1 (HMGB-1) and matrix metalloproteinase-9 (MMP-9) in non-small cell lung cancer (NSCLC).
    Wang JL; Wu DW; Cheng ZZ; Han WZ; Xu SW; Sun NN
    Asian Pac J Cancer Prev; 2014; 15(12):4865-9. PubMed ID: 24998555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Poor prognosis of NSCLC located in lower lobe is partly mediated by lower frequency of EGFR mutations.
    Lee HW; Park YS; Park S; Lee CH
    Sci Rep; 2020 Sep; 10(1):14933. PubMed ID: 32913267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of cofilin‑1 and Twist‑1 protein expression in human non‑small cell lung cancer tissues.
    Chang CY; Chang SL; Leu JD; Chang YC; Hsiao M; Lin LT; Lin HN; Lee YJ
    Oncol Rep; 2019 Aug; 42(2):805-816. PubMed ID: 31233187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.
    Beau-Faller M; Pencreach E; Leduc C; Blons H; Merlio JP; Bringuier PP; de Fraipont F; Escande F; Lemoine A; Ouafik L; Denis M; Hofman P; Lacave R; Melaabi S; Langlais A; Missy P; Morin F; Moro-Sibilot D; Barlesi F; Cadranel J;
    Lung Cancer; 2020 Feb; 140():19-26. PubMed ID: 31841714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genome-wide interrogation identifies YAP1 variants associated with survival of small-cell lung cancer patients.
    Wu C; Xu B; Yuan P; Miao X; Liu Y; Guan Y; Yu D; Xu J; Zhang T; Shen H; Wu T; Lin D
    Cancer Res; 2010 Dec; 70(23):9721-9. PubMed ID: 21118971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cryobiopsy increases the EGFR detection rate in non-small cell lung cancer.
    Haentschel M; Boeckeler M; Ehab A; Wagner R; Spengler W; Steger V; Boesmueller H; Horger M; Lewis RA; Fend F; Kanz L; Bonzheim I; Hetzel J
    Lung Cancer; 2020 Mar; 141():56-63. PubMed ID: 31955001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Up-Regulation of miR-21 Expression Predicate Advanced Clinicopathological Features and Poor Prognosis in Patients with Non-Small Cell Lung Cancer.
    Tian L; Shan W; Zhang Y; Lv X; Li X; Wei C
    Pathol Oncol Res; 2016 Jan; 22(1):161-7. PubMed ID: 26453197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
    Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
    Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic role of Rab27A and Rab27B expression in patients with non-small cell lung carcinoma.
    Koh HM; Song DH
    Thorac Cancer; 2019 Feb; 10(2):143-149. PubMed ID: 30480360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.
    Ikeda S; Okamoto T; Okano S; Umemoto Y; Tagawa T; Morodomi Y; Kohno M; Shimamatsu S; Kitahara H; Suzuki Y; Fujishita T; Maehara Y
    J Thorac Oncol; 2016 Jan; 11(1):62-71. PubMed ID: 26762740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry - Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort.
    Rulle U; Tsourti Z; Casanova R; Deml KF; Verbeken E; Thunnissen E; Warth A; Cheney R; Sejda A; Speel EJ; Madsen LB; Nonaka D; Navarro A; Sansano I; Marchetti A; Finn SP; Monkhorst K; Kerr KM; Haberecker M; Wu C; Zygoura P; Kammler R; Geiger T; Gendreau S; Schulze K; Vrugt B; Wild P; Moch H; Weder W; Ciftlik AT; Dafni U; Peters S; Bubendorf L; Stahel RA; Soltermann A
    J Thorac Oncol; 2018 Dec; 13(12):1851-1863. PubMed ID: 30240851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bis Expression in Patients with Surgically Resected Lung Cancer and its Clinical Significance.
    Yeo CD; Park GS; Kang N; Choi SY; Kim HY; Lee DS; Kim YS; Kim YK; Park JG; Sung SW; Lee KY; Park MS; Yim HW; Kim SJ; Lee JH
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1365-70. PubMed ID: 25968616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AKT1 polymorphisms and survival of early stage non-small cell lung cancer.
    Kim MJ; Kang HG; Lee SY; Jeon HS; Lee WK; Park JY; Lee EB; Lee JH; Cha SI; Kim DS; Kim CH; Kam S; Jung TH; Park JY
    J Surg Oncol; 2012 Feb; 105(2):167-74. PubMed ID: 21842521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel association between CD74 polymorphisms and hematologic toxicity in patients with NSCLC after platinum-based chemotherapy.
    Tan X; Wu Q; Cai Y; Zhao X; Wang S; Gao Z; Yang Y; Li X; Qian J; Wang J; Su B; Chen H; Han B; Jiang G; Lu D
    Clin Lung Cancer; 2014 Jan; 15(1):67-78.e12. PubMed ID: 24220096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.